Cash and cash equivalents were $56.2 million at December 31, 2022, compared to $106.1 million at December 31, 2021. The company had $25.0 million of debt principal under a capital credit facility with K2 HealthVentures, which remains currently outstanding.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on APTX:
- Biotech Alert: Searches spiking for these stocks today
- Aptinyx downgraded to Neutral from Buy at H.C. Wainwright
- SVB Securities downgrades Aptinyx to Market Perform, lowers price target to 50c
- Aptinyx downgraded to Market Perform from Outperform at SVB Securities
- APTX Nosedives after Parkinson’s and Dementia Phase 2 Study Disappoints